Skip to main content
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
60.40
+6.45 (11.96%)
Mar 10, 2026, 2:24 PM HKT

HKG:2315 Revenue

In the year 2025, Biocytogen Pharmaceuticals (Beijing) had annual revenue of 1.38B CNY with 40.63% growth. Biocytogen Pharmaceuticals (Beijing) had revenue of 620.96M in the half year ending June 30, 2025, with 89.99% growth.

Revenue
1.38B CNY
Revenue Growth
+40.63%
P/S Ratio
22.99
Revenue / Employee
1.06M CNY
Employees
1,306
Market Cap
35.28B HKD

Revenue Chart

* This company reports financials in CNY.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20251.38B398.35M40.63%
Dec 31, 2024980.45M263.54M36.76%
Dec 31, 2023716.91M183.03M34.28%
Dec 31, 2022533.88M179.33M50.58%
Dec 31, 2021354.56M101.01M39.84%
Dec 31, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Shanghai Henlius Biotech 6.35B
Shanghai Junshi Biosciences 2.78B
Duality Biotherapeutics 2.38B
Genscript Biotech 6.50B
InnoCare Pharma 1.56B
PegBio -4.25M
3SBio 9.94B
RemeGen 3.62B
Revenue Rankings

Biocytogen Pharmaceuticals (Beijing) News

More News